Drug Profile
Research programme: pain therapeutics - Ensysce Biosciences
Alternative Names: PF-14Latest Information Update: 24 Feb 2016
Price :
$50
*
At a glance
- Originator PharmacoFore
- Developer Ensysce Biosciences
- Class Opioid analgesics
- Mechanism of Action Opioid receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Inflammatory pain
Most Recent Events
- 24 Feb 2016 Discontinued for Inflammatory pain in USA (unspecified route)
- 19 Jan 2016 Signature Therapeutics has merged into Ensysce Biosciences
- 03 Sep 2012 PharmacoFore is now called Signature Therapeutics